Pharmaceutical Executive September 9, 2022

And, in equal measure, patients and doctors—as EU mulls new rules.

The announcement of a new EU plan for wider sharing of health data has won endorsement from across the health community—but this is sensitive territory, so unsurprisingly the detailed reactions vary widely, depending on whether it’s industry, patients, or healthcare professionals doing the talking.

Predictably, pharmaceutical companies in this familiar battle-ground are keen to get their hands on as much data as possible to further their own product development plans. Equally predictably, patients and doctors tend to focus on protecting privacy and ensuring data security. What is surprising this time round is that the proposal has prompted the expression of strong opinions on a previously unexplored area of health-data...

Today's Sponsors


Today's Sponsor


Topics: Big Data, Biotechnology, Pharma, Pharma / Biotech, Technology
How digital health companies are capitalizing on the GLP-1 boom
Journalists Zero In on Bird Flu and Weight Loss Drugs
GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials
Chasing the alchemy of trial diversity with a mix of culture change and practical mechanics
Ozempic Drug Semaglutide Could Protect Kidneys, Study Finds

Share This Article